Tigerase® Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19

Sponsor
AO GENERIUM (Industry)
Overall Status
Completed
CT.gov ID
NCT04459325
Collaborator
(none)
100
Enrollment
6
Locations
2
Arms
1.6
Actual Duration (Months)
16.7
Patients Per Site
10.4
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

It is a multicenter, open-label, randomized, parallel-group study of the efficacy and safety of Tigerase® (GENERIUM JSC, Russia) with standard therapy versus standard therapy in patients with COVID-19.

Condition or DiseaseIntervention/TreatmentPhase
  • Biological: Tigerase® and best available care
  • Other: Best available care
Phase 3

Detailed Description

COVID-19 (Coronavirus disease-19) is an acute respiratory infectious disease caused by SARS-CoV-2 coronavirus. The spread of the disease quickly developed to the global pandemic in March-April 2020, and was characterized by acute respiratory distress syndrome (ARDS) in 10-15% of cases, which leads to a high frequency of hospitalization in the intensive care unit and high mortality. The search for effective treatment and reducing the severity of COVID-19 is a priority in the development of medical science.

One of the key processes of the innate immune system are neutrophil extracellular traps (NET), formed by neutrophils when they eject their DNA from the cytoplasm. NET is most often described as a mechanism for capturing bacteria in order to limit their spread. In addition, NET also plays a role in antiviral immunity. In particular, viral infections lung damage is at least partially due to NET.

This suggests that drug disruption of NET in COVID-19 is promising. DNase preparations, and in particular Tigerase®, are safe and effective for the treatment of cystic fibrosis and can serve as a NET destruction agent in patient with COVID-19.

Study Design

Study Type:
Interventional
Actual Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Prospective Open-label Study of the Tigerase® Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19
Actual Study Start Date :
Jun 1, 2020
Actual Primary Completion Date :
Jul 20, 2020
Actual Study Completion Date :
Jul 20, 2020

Arms and Interventions

ArmIntervention/Treatment
Experimental: Study drug and best available care

Best available care and Tigerase®/nebulised dornase alfa [2.5 mg BID] for 7 days

Biological: Tigerase® and best available care
Nebulised dornase alfa [2.5 mg BID] for 7 days
Other Names:
  • Dornase Alfa Inhalation Solution and best available care
  • Other: Control group (best available care)

    Patients will receive the usual care in accordance with good practice.

    Other: Best available care
    Patients will receive the usual care in accordance with good practice.
    Other Names:
  • Standard of care
  • Outcome Measures

    Primary Outcome Measures

    1. The proportion of patients with mechanical ventilation [Day 8]

    2. Category change on WHO Ordinal Scale for Clinical Improvement [Day 8]

    Secondary Outcome Measures

    1. The proportion of patients with mechanical ventilation [Day 28]

    2. Category change on WHO Ordinal Scale for Clinical Improvement [Day 28]

    3. Proportion of patients surviving 28 days after inclusion in the study [Day 28]

    4. Number of days of oxygen therapy during the treatment period [Day 8]

    5. Change in C-reactive protein level [Days 3, 5, 8]

    6. Change in oxygenation index [Days 3, 5, 8]

      PaO2 / FiO2, FiO2 = fraction of oxygen in inhaled air,% PaO2 = partial pressure of oxygen in arterial blood, mm Hg

    7. Change in SpO2/FiO2 index [Days 1, 2, 3, 4, 5, 6, 7, 8]

      SpO2 / FiO2, FiO2 = fraction of oxygen in inhaled air,% SpO2 = hemoglobin oxygen saturation, %

    8. Change in ferritin level [Days 3, 5, 8]

    9. Change in D-dimer level [Days 3, 5, 8]

    10. Change in neutrophil-leucocyte ratio [Days 3, 5, 8]

    11. Change in leucocyte-C-reactive protein ratio [Days 3, 5, 8]

    12. Change in the level of relative (%) number of lymphocytes of the general blood test [Days 3, 5, 8]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. Written informed consent for participation in the study

    2. Men and women aged ≥18 years

    3. Laboratory-confirmed diagnosis of coronavirus infection caused by COVID19, moderate severity *

    *Criteria for moderate flow (just one point) Mandatory Criterion

    • Pneumonia Additional criteria (used to characterize the disease and are not required to determine the severity)

    • Fever above 38 ° C

    • respiratory rate more than 22 / min

    • Shortness of breath during physical exertion

    • SpO2 <95%

    • С-reactive protein (CRP) of serum more than 10 mg / l

    1. Patients with pneumonia with a stable level of hemoglobin saturation by oxygen (> 93%) on oxygen support and / or receiving respiratory support of non-invasive mechanical ventilation
    Exclusion Criteria:
    1. Individual intolerance or hypersensitivity to the active or any of the excipients of the drug Tigerase®

    2. The need for invasive mechanical ventilation at the time of inclusion of the patient

    3. Patients severe condition (one of the following characteristics):

    • Respiratory distress syndrome with respiratory rate ≥30 per minute

    • Saturation of hemoglobin with oxygen ≤93% with oxygen support

    1. Patient participate in any clinical trials and / or taking the experimental drug within 30 days before inclusion this trial

    2. Severe competitive respiratory system diseases (bronchial asthma, chronic obstructive pulmonary disease - COPD, cystic fibrosis, interstitial lung disease)

    3. Positive results of laboratory testing for HIV and hepatitis B and C

    4. Life expectancy less than 12 months without COVID-19

    5. Other diseases and conditions, significant laboratory or instrumental deviation, which, according to investigator opinion, may impact the results of the study, limit the patient's participation in the trial or create an unreasonable risk for the patient

    6. Patient's unwillingness or disability to comply with the recommendations prescribed by protocol, as well as any concomitant medical or serious mental conditions that render the patient unsuitable for participation in the study, limit the legitimacy of obtaining informed consent or may affect the patient's ability to participate in the study (including disability to use a nebulizer)

    7. Positive pregnancy test in women

    8. The period of breastfeeding in women

    9. Refusal of male patients and female patients with preserved reproductive function to use adequate methods of contraception throughout the study and for at least 30 days after the end of therapy with the studied drug

    Contacts and Locations

    Locations

    SiteCityStateCountryPostal Code
    1City Clinical Hospital #15MoscowRussian Federation111539
    2I.M. Sechenov First Moscow State Medical University (Sechenov University)MoscowRussian Federation119991
    3City Clinical Hospital #51MoscowRussian Federation121309
    4City Clinical Hospital #52MoscowRussian Federation123182
    5N.V. Sklifosovsky Scientific Research Institute of First AidMoscowRussian Federation129090
    6Siberian State Medical University (SibMed)MoscowRussian Federation634050

    Sponsors and Collaborators

    • AO GENERIUM

    Investigators

    • Study Chair: Oksana A. Markova, MD, AO GENERIUM

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    AO GENERIUM
    ClinicalTrials.gov Identifier:
    NCT04459325
    Other Study ID Numbers:
    • DRN-ALI-III
    • #216 eff date 27.05.2020
    First Posted:
    Jul 7, 2020
    Last Update Posted:
    Oct 14, 2020
    Last Verified:
    Jul 1, 2020
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by AO GENERIUM
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 14, 2020